Developer · CLN · Poland
Celon Pharma S.A.
Polish pharmaceutical company headquartered in Kazun Nowy near Warsaw, listed on the Warsaw Stock Exchange (WSE: CLN). Combines a generics business with an in-house innovative R&D pipeline; its CNS assets include the PDE10A inhibitor alofropodect (CPL'36 / CPL500036) for schizophrenia and levodopa-induced dyskinesia, and Falkieri (inhaled esketamine) for treatment-resistant depression.
Pipeline (1)
- SchizophreniaPhase 2Active
- Levodopa-induced dyskinesia in Parkinson's diseasePhase 2Active
Catalysts · 0 upcoming · 3 reported
Recently reported
- 2026-07-31met
AlofropodectforSchizophreniaFull results
Peer-reviewed Phase 2 results published in CNS Drugs: both doses met the PANSS positive primary endpoint (-3.70 and -6.35 vs placebo); response rate (>=30% PANSS total reduction) 3.8% placebo, 15.4% 20 mg, 42.3% 40 mg.
- 2025-03-04met
AlofropodectforLevodopa-induced dyskinesia in Parkinson's diseaseTopline data
Phase 2 in levodopa-induced dyskinesia (n=105) met its primary endpoint: CPL'36 improved UDysRS total by 12.30 (20 mg) and 13.58 (40 mg) units vs placebo (both p<0.001).
- 2024-07-05met
AlofropodectforSchizophreniaTopline data
Phase 2 in acute schizophrenia (n=189) met its primary endpoint: CPL'36 improved PANSS positive by 3.7 (20 mg) and 6.3 (40 mg) points vs placebo, and PANSS total by 9.7 and 16.4 points (all p<0.001).
Recent activity
- Jul 31, 2026ReadoutAlofropodect·SchizophreniametPeer-reviewed Phase 2 results published in CNS Drugs: both doses met the PANSS positive primary endpoint (-3.70 and -6.35 vs placebo); response rate (>=30% PANSS total reduction) 3.8% placebo, 15.4% 20 mg, 42.3% 40 mg.source ↗
- Oct 8, 2025Phase changeAlofropodect·SchizophreniaPhase 2Celon announced positive FDA feedback from a Type B meeting: existing preclinical data are sufficient to start pivotal studies; the FDA endorsed a Phase 3 program of two 28-day acute trials plus a 12-month open-label extension. Celon expects to start pivotal studies in 2026. Program kept at phase_2 until a Phase 3 trial starts.source ↗
- Mar 4, 2025ReadoutAlofropodect·Levodopa-induced dyskinesia in Parkinson's diseasemetPhase 2 in levodopa-induced dyskinesia (n=105) met its primary endpoint: CPL'36 improved UDysRS total by 12.30 (20 mg) and 13.58 (40 mg) units vs placebo (both p<0.001).source ↗
- Jan 27, 2025Phase changeAlofropodect·Levodopa-induced dyskinesia in Parkinson's diseasePhase 2NCT05297201 completed (primary completion 2025-01-13, study completion 2025-01-27) with 105 participants enrolled.source ↗
- Jul 5, 2024ReadoutAlofropodect·SchizophreniametPhase 2 in acute schizophrenia (n=189) met its primary endpoint: CPL'36 improved PANSS positive by 3.7 (20 mg) and 6.3 (40 mg) points vs placebo, and PANSS total by 9.7 and 16.4 points (all p<0.001).source ↗
- Jun 19, 2024Phase changeAlofropodect·SchizophreniaPhase 2NCT05278156 completed (primary completion 2024-06-05, study completion 2024-06-19), 189 participants enrolled.source ↗
- Nov 2, 2021Phase changeAlofropodect·Levodopa-induced dyskinesia in Parkinson's diseasePhase 2Phase 2 randomised, placebo-controlled study NCT05297201 in levodopa-induced dyskinesia started (CPL500036 20 mg or 40 mg once daily vs placebo for 28 days; primary endpoint change in UDysRS total score at Week 4).source ↗
- May 19, 2021Phase changeAlofropodect·SchizophreniaPhase 2Phase 2 randomised, double-blind, placebo-controlled study NCT05278156 in acute schizophrenia started (189 patients; CPL500036 20 mg or 40 mg once daily vs placebo for 28 days; primary endpoint change in PANSS positive subscale at Day 28).source ↗
- Sep 16, 2019Phase changeAlofropodect·SchizophreniaPhase 1First-in-human single and multiple ascending dose study in healthy volunteers (NCT03873324, 56 participants, Poland) completed; started 2018-12-20.source ↗
Competitive landscape
Other companies developing against Celon Pharma S.A.'s targets or indications.
- Merck & Co., Inc.1 compoundPDE10ASchizophrenia
- Alkermes plc1 compoundSchizophrenia
- Alto Neuroscience, Inc.1 compoundSchizophrenia
- Avanir Pharmaceuticals1 compoundSchizophrenia
- BioXcel Therapeutics, Inc.1 compoundSchizophrenia
- Boehringer Ingelheim2 compoundsSchizophrenia
- Cerevel Therapeutics1 compoundSchizophrenia
- Eli Lilly and Company2 compoundsSchizophrenia
- F. Hoffmann-La Roche Ltd1 compoundSchizophrenia
- Intra-Cellular Therapies, Inc.1 compoundSchizophrenia
- Jiangsu Hansoh Pharmaceutical Co., Ltd.1 compoundSchizophrenia
- Karuna Therapeutics1 compoundSchizophrenia